Table 4.
NF-κB target genes that were differentially transcribed and can be a possible drug target of N. vitripennis venom. Three different comparisons are presented: venom-treated versus untreated, venom- and LPS-treated versus LPS-treated cells and LPS-treated versus untreated. When p > 0.05, insignificant values are between brackets; when |FR| >2, values are in bold. (Abb = abbreviation; FR = fold regulation; Ref = reference).
| Possible drug targets of venom | Abb | FR venom versus untreated | FR venom- and LPS- treated versus LPS-treated | FR LPS-treated versus untreated | Potential targeted diseases | Reference |
|---|---|---|---|---|---|---|
| NAD(P)H dehydrogenase, quinone 1 | Nqo1 | 24.64 | (3.014) | (−1.247) | acute leukemia | [52] |
| Cyclin D1 | Ccnd1 | −2.67 | −7.44 | −5.05 | breast cancer | [53] |
| Interferon regulatory factor 1 | Irf1 | (2.039) | 13.95 | 2.95 | breast cancer | [51] |
| Matrix metallopeptidase 9 | Mmp9 | (1.635) | −5.80 | 17.82 | cancer | [54] |
| Colony stimulating factor 3 (granulocyte) | Csf3 | 5.49 | −31.72 | 15,821.68 | inflammatory arthritis | [49] |
| Interleukin 1 beta | Il1b | 5.88 | −4.39 | 15,647.33 | autoinflammatory diseases | [55] |
| Complement factor B | Cfb | (−1.007) | −4.20 | 14.68 | complement mediated inflammatory diseases | [56] |